急性大血管闭塞:直接取栓与桥接取栓的匹配对照研究
本研究基于中国ANGEL-ACT前瞻性登记数据库,纳入2017年11月至2019年3月26省111家医院接受血管内治疗的急性大血管闭塞患者,比较直接机械取栓与静脉溶栓联合取栓的疗效与安全性。经1:1倾向评分匹配后788例分析显示,两组90天改良Rankin量表评分和成功再通率无显著差异,但直接取栓组入院至穿刺时间更短、症状性颅内出血和术中栓塞发生率更低。
要点
- 直接取栓与联合取栓的90天功能预后和成功再通率无显著差异
- 直接取栓组入院至穿刺时间更短(中位112 vs 136分钟)
- 直接取栓组症状性颅内出血和术中栓塞风险更低
核心结论
- 在真实世界实践中,直接机械取栓对急性大血管闭塞患者的疗效与静脉溶栓联合取栓相似。
- 直接取栓可能与更短的入院至穿刺时间、更低的症状性颅内出血和栓塞风险相关。
研究设计与样本
- 基于ANGEL-ACT前瞻性全国登记数据库的匹配对照研究。
- 纳入2017年11月至2019年3月26省111家医院接受血管内治疗的急性大血管闭塞患者。
- 共纳入1026例(直接取栓组600例,联合组426例),经1:1倾向评分匹配后788例进入分析。
主要发现
- 匹配后两组90天改良Rankin量表评分中位数均为3分(P=0.82)。
- 成功再通率直接取栓组86.6% vs 联合组89.3%(P=0.23)。
- 入院至穿刺时间中位112 vs 136分钟(β=−45.02,95%CI −68.31至−21.74)。
- 症状性颅内出血发生率5.5% vs 10.1%(OR 0.52,95%CI 0.30–0.91)。
- 术中栓塞发生率4.6% vs 8.1%(OR 0.54,95%CI 0.30–0.98)。
临床怎么用
- 对于符合静脉溶栓条件的急性大血管闭塞患者,直接取栓可作为联合取栓的替代策略。
- 直接取栓可能缩短入院至穿刺时间并降低症状性颅内出血和栓塞风险。
局限性
- 本研究为匹配对照研究而非随机对照试验,可能存在未测量混杂。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A recent randomized controlled trial DIRECT-MT (Direct Intra-Arterial Thrombectomy to Revascularize AIS Patients With Large Vessel Occlusion Efficiently in Chinese Tertiary Hospitals) compared the safety and efficacy of mechanical thrombectomy (MT) versus combined intravenous thrombolysis (IVT) and MT for acute large vessel occlusion. The current study utilized a prospective, nationwide registry to validate the results of the DIRECT-MT trial in a real-world practice setting. Subjects were selected from a prospective cohort of acute large vessel occlusion patients undergoing endovascular treatment at 111 hospitals from 26 provinces in China (ANGEL-ACT registry [Endovascular Treatment Key Technique and Emergency Work Flow Improvement of Acute Ischemic Stroke]) between November 2017 and March 2019. All patients eligible for IVT and receiving MT were reviewed and then grouped according to whether prior IVT or not (MT and combined IVT+MT). After a 1:1 propensity score matching, the outcome measures including the 90-day modified Rankin Scale, successful recanalization, door-to-puncture time, symptomatic intracranial hemorrhage, and intraprocedural embolization were compared. A total of 1026 patients, 600 in the MT group and 426 in the combined group, were included. Among 788 patients identified after matching, there were no significant differences in the 90-day modified Rankin Scale (median, 3 versus 3 points; P=0.82) and successful recanalization (86.6% versus 89.3%; P=0.23) between the two groups; however, patients of the MT group had a shorter door-to-puncture time (median, 112 versus 136 minutes; β=−45.02 [95% CI, −68.31 to −21.74]), lower rates of symptomatic intracranial hemorrhage (5.5% versus 10.1%; odds ratio, 0.52 [95% CI, 0.30–0.91]), and embolization (4.6% versus 8.1%; odds ratio, 0.54 [95% CI, 0.30–0.98]) than those of the combined group. This matched-control study largely confirmed the findings of the DIRECT-MT trial in a real-world practice setting, suggesting that MT may carry similar effectiveness to combined IVT+MT for acute large vessel occlusion patients, despite MT alone seems to be associated with a shorter in-hospital delay until procedure, lower risks of symptomatic intracranial hemorrhage, and embolization. URL: https://www.clinicaltrials.gov; Unique identifier: NCT03370939
引用
- Tong X, Wang Y, Fiehler J, et al. Thrombectomy Versus Combined Thrombolysis and Thrombectomy in Patients With Acute Stroke: A Matched-Control Study. Stroke. 2021. PMID: 33657849. doi:10.1161/STROKEAHA.120.031599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。